Additive roles of platelets and fibrinogen in whole-blood fibrin clot formation upon dilution as assessed by thromboelastometry

Summary

Blood dilution after transfusion fluids leads to diminished coagulant activity monitored by rotational thromboelastometry, assessing elastic fibrin clot formation, or by thrombin generation testing. We aimed to determine the contributions of blood cells (platelets, red blood cells) and plasma factors (fibrinogen, prothrombin complex concentrate) to fibrin clot formation under conditions of haemodilution in vitro or in vivo. Whole blood or plasma diluted in vitro was supplemented with platelets, red cells, fibrinogen or prothrombin complex concentrate (PCC). Thromboelastometry was measured in whole blood as well as plasma; thrombin generation was determined in parallel. Similar tests were performed with blood from 48 patients, obtained before and after massive fluid infusion during cardiothoracic surgery. Addition of platelets or fibrinogen, in additive and independent ways, reversed the impaired fibrin clot formation (thromboelastometry) in diluted whole blood. In contrast, supplementation of red blood cells or prothrombin complex concentrate was ineffective. Platelets and fibrinogen independently restored clot formation in diluted plasma, resulting in thromboelastometry curves approaching those in whole blood. In whole blood from patients undergoing dilution during surgery, elastic clot formation was determined by both the platelet count and the fibrinogen level. Thrombin generation in diluted (patient) plasma was not changed by fibrinogen, but improved markedly by prothrombin complex concentrate. In conclusion, in dilutional coagulopathy, platelets and fibrinogen, but not red blood cells or vitamin K-dependent coagulation factors, independently determine thromboelastometry parameters measured in whole blood and plasma. Clinical decisions for transfusion based on thromboelastometry should take into account the platelet concentration.

Keywords

Blood dilution - coagulation - fibrin clot formation - thrombin generation - platelets

^* Equal contribution of these authors.

• References

• 1 Brenni M, Worn M, Bruesch M. et al. Successful rotational thromboelasto-metry-guided treatment of traumatic haemorrhage, hyperfibrinolysis and coagulopathy. Acta Anaesthesiol Scand 2010; 54: 111-117.
• 2 Tirosh-Wagner T, Strauss T, Rubinshtein M. et al. Point of care testing in children undergoing cardiopulmonary bypass. Pediatr Blood Cancer 2011; 56: 794-798.
• 3 Wegner J, Popovsky MA. Clinical utility of thromboelastography: one size does not fit all. Semin Thromb Haemost 2010; 36: 699-706.
• 4 Schochl H, Nienaber U, Hofer G. et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010; 14: R55
• 5 Schols SE, Lance MD, Feijge MA. et al. Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery. Thromb Haemost 2010; 103: 318-328.
• 6 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
• 7 Baglin T. The measurement and application of thrombin generation. Br J Hae- matol 2005; 130: 653-661.
• 8 Schols SE, Heemskerk JW, van Pampus EC. Correction of coagulation in dilu-tional coagulopathy: use of kinetic and capacitive coagulation assays to improve haemostasis. Transfus Med Rev 2010; 24: 44-52.
• 9 Callow CR, Swindell R, Randall W. et al. The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. Br J Haematol 2002; 118: 677-682.
• 10 Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ. et al. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth 2008; 101: 769-773.
• 11 Thorarinsdottir HR, Sigurbjornsson FT, Hreinsson K. et al. Effects of fibrinogen concentrate administration during severe haemorrhage. Acta Anaesthesiol Scand 2010; 54: 1077-1082.
• 12 Lance MD, Ninivaggi M, Schols SE. et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sang 2012; 103: 25-34.
• 13 Demeyere R, Gillardin S, Arnout J. et al. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang 2010; 99: 251-260.
• 14 Rahe-Meyer N, Sorensen B. For: Fibrinogen concentrate for management of bleeding. J Thromb Haemost 2011; 9: 1-5.
• 15 Dickneite G, Doerr B, Kaspereit F. Characterisation of the coagulation deficit in porcine dilutional coagulopathy and substitution with a prothrombin complex concentrate. Anesth Analg 2008; 106: 1070-1077.
• 16 Dickneite G, Pragst I. Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model. Br J Anaesth 2009; 102: 345-354.
• 17 Fries D, Haas T, Klingler A. et al. Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy-- a porcine model. Br J Anaesth 2006; 97: 460-467.
• 18 Rosing J, Tans G, Govers-Riemslag JW. et al. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255: 274-283.
• 19 Schols SE, Feijge MA, Lance MD. et al. Effects of plasma dilution on tissue-factor-induced thrombin generation and thromboelastography: partly compensating role of platelets. Transfusion 2008; 48: 2384-2394.
• 20 Vanschoonbeek K, Feijge MA, Van Kampen RJ. et al. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost 2004; 2: 476-484.
• 21 Schols SE, van der Meijden PE, van Oerle R. et al. Increased thrombin generation and fibrinogen level after therapeutic plasma transfusion: relation to bleeding. Thromb Haemost 2008; 99: 64-70.
• 22 Bochsen L, Johansson PI, Kristensen AT. et al. The influence of platelets, plasma and red blood cells on functional haemostatic assays. Blood Coagul Fibrinolysis 2011; 22: 167-175.
• 23 Jensen AS, Johansson PI, Idorn L. et al. The haematocrit - an important factor causing impaired haemostasis in patients with cyanotic congenital heart disease. Int J Cardiol 2013; 167: 1317-1321.
• 24 Nagler M, Kathriner S, Bachmann LM. et al. Impact of changes in haematocrit level and platelet count on thromboelastometry parameters. Thromb Res 2013; 131: 249-253.
• 25 Heemskerk JW, Mattheij NJ, Cosemans JM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost 2013; 11: 2-16.
• 26 Weiss G, Lison S, Spannagl M. et al. Expressiveness of global coagulation parameters in dilutional coagulopathy. Br J Anaesth 2010; 105: 429-436.
• 27 Dickneite G, Pragst I, Joch C. et al. Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P). Blood Coagul Fibrinolysis 2009; 20: 535-540.
• 28 Grottke O, Braunschweig T, Spronk HM. et al. Increasing concentrations of pro-thrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. Blood 2011; 118: 1943-1951.
• 29 Grottke O, Rossaint R, Henskens Y. et al. Thrombin generation capacity of pro-thrombin complex concentrate in an in vitro dilutional model. PLoS One 2013; 8: e64100
• 30 Castoldi E, Rosing J. Thrombin generation tests. Thromb Res 2011; 127 (Suppl. 03) S21-25.